The ErbB receptor family: A therapeutic target for cancer

Trends in Molecular Medicine

Volumn 8, Issue 4 SUPPL., 2002, Pages

  De Bono, Johann S ^a   Rowinsky, Eric K ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; ERLOTINIB; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; TYROSINE KINASE RECEPTOR;

ANTINEOPLASTIC ACTIVITY; CANCER; CELL PROLIFERATION; DRUG MECHANISM; HUMAN; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS; ENZYME INHIBITORS; FEMALE; HUMANS; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 0036214044     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4914(02)02306-7     Document Type: Review

References (43)

1. Cell signaling by receptor tyrosine kinases
2. Receptor tyrosine kinases: Specific outcomes from general signals
3. Epidermal growth factor-related peptides and their receptors in human malignancies
4. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor
5. The EGF receptor family as targets for cancer therapy
6. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: Progression from reversible to irreversible inhibitors
7. The EGFR as a target for anticancer therapy - Focus on cetuximab
8. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy
9. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo
10. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck
11. Epidermal growth factor receptor-targeted therapy with C22S and cisplatin in patients with head and neck cancer
12. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy
13. ABX-EGF: A fully humanized anti-EGF receptor antibody in patients with advanced cancer
14. A phase I trial of the epidermal growth factor receptor (EGFR)-directed bispecific antibody (BsAB) MDX-447 in patients with solid tumors
15. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
16. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase
17. Phase I dose escalation study of anti-epidermal growth factor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774 in patients with advanced solid tumors
18. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
19. 1 BFDG-PET evaluation of patients treated with the epidermal growth factor (EGFR) tyrosine kinase (TK) inhibitor, CP-358,774
20. A phase II trial of the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients with advanced, EGFR-expressing, non-small cell lung cancer
21. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian cancer
22. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck
23. A phase I and pharmacokinetic study of Cl-1033, a pan-ErbB tyrosine kinase inhibitor, given orally on days 1, 8, and 15 every 28 days to patients with solid tumors
24. EKB-569: A new irreversible inhibitor of EGFR tyrosine kinase for the treatment of cancer
25. Mechanism of action of trastuzumab and scientific update
26. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification
27. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
28. Development of clinical trial of EIA gene therapy targeting HER-2/neu-overexpressing breast and ovarian cancer
29. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel
30. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay
31. Inhibition of the epidermal growth factor receptor by OSI-774, a specific EGFR inhibitor in malignant and normal tissues of cancer patients
32. Anticancer agents targeting signaling molecules and cancer cell environment: Challenges for drug development?
33. There are no bad anticancer agents, only bad clinical trial designs: Twenty-first Richard and Hinda Rosenthal Foundation Award Lecture
34. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
35. Monoclonal antibody IMC-C225, an anti-epidermal growth factor receptor, for patients with EGFR-positive tumors refractory to or in relapse from previous therapeutic regimens
36. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer
37. Efficacy and safety of the anti-epidermal growth factor antibody IMC-C225 in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck refractory to cisplatin containing chemotherapy
38. Phase II study of anti-epidermal growth factor receptor antibody cetuximab in combination with gemcitabine in patients with advanced pancreatic cancer
39. Cetuximab plus irinotecan is active in CPT-11-refractory colorectal cancer that expresses epidermal growth factor receptor
40. Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor, shows evidence of good tolerability and activity: Final result from a phase I. Study
41. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected tumor types: Evidence of activity and good tolerability
42. Final results of a phase I intermittent dose-escalation trial of ZD1839 (Iressa) in Japanese patients with various solid tumors
43. Final results of the dose escalation phase of a phase I pharmacokinetics, pharmacodynamic and biological activity study of ZD1839: NCIC CTG IND. 122